Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director · Chief Executive Officer | March 20, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date March 20, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,000 |
Reported balance
After 2026-03-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-20 · Grant · Acquired 75,000 · Balance 180,000 F1: See remarks |
Filing footnotes · ownership attribution and instrument terms
F1: See remarks
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2026 Filed Mar 23, 2026 13:48 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-001843 · ownership.xml · nonDerivative · entry 1 Duke John D · CIK 0002071593 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 F1 · balance_after: See remarks Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:56 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 5,000 | $5.01 | $25,050.00 |
DisclosureSEC source: 0001171843-26-001645 · ownership.xml · nonDerivative · entry 1 Duke John D · CIK 0002071593 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 F1 · balance_after: Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) an award of 50,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person and (c) an award of 50,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported. F2 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 50,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 500,000 restricted stock units and the 50,000 restricted stock units referenced in Footnote 1(c) were previously reported as covering 500,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 01:09 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-076302 · tm2523107-1_4seq1.xml · nonDerivative · entry 2 Duke John D · CIK 0002071593 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 F2 · shares: Represents an award of 500,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported. F3 · balance_after: Includes the awards described in footnotes (1) and (2) above. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 01:09 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-076302 · tm2523107-1_4seq1.xml · nonDerivative · entry 1 Duke John D · CIK 0002071593 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 F1 · shares: Represents an award of 500,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.